Clinical trials: GAD
Dysthymic Disorder
Desvenlafaxine Monotherapy in Dysthymia
This multi-centred study will be conducted at two centres. The design will be an open label, flexible-dose study. This investigation will evaluate the efficacy of Desvenlafaxine monotherapy for patients who meet diagnostic…
- Trial name
- NCT01948895
- Testing
- Desvenlafaxine
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Anxiety Disorders
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
- Trial name
- NCT00108836
- Testing
- XBD173
- Where
- 23 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
CES, Anxiety Disorders and Symptoms
CES in the Elderly With Generalized Anxiety Disorders
The study aimed to investigate whether cranial electrotherapy stimulation(CES) could benefit anxiety symptoms, depressive symptoms, quality of sleep and quality of life in elderly patients with anxiety disorder.
- Trial name
- NCT04465136
- Testing
- CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)
- Where
- Taiwan
- Volunteers
- 27 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Anxiety
Pediatric Anxiety Intervention With an Entertaining Video Game: Feasibility Study
This research study aims to test the feasibility and effectiveness of using an entertaining video game as an addition to traditional therapy for the treatment of anxiety disorders in youth, particularly those youth who may have…
- Trial name
- NCT02713425
- Testing
- Entertaining Video Game
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Major Depressive Disorder, Dysthymic Disorder
Quetiapine in Co-Morbid Depressive and Anxiety Disorders
This multi-centred study will be conducted at three centres. The design will be a randomized, placebo-controlled, parallel-group one.
- Conditions
- Major Depressive Disorder, Dysthymic Disorder, Anxiety Disorders, Generalized Anxiety Disorder
- Trial name
- NCT00688818
- Testing
- Quetiapine
- Where
- 4 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder, Attention Deficit Disorder With Hyperactivity
Brain Imaging and Computer Games in Children With Either Bipolar Disorder, ADHD, Anxiety or Healthy Controls
The purpose of this research is to learn more about how children with mental health problems, including bipolar disorder (BD), attention deficit hyperactivity disorder (ADHD), and generalized anxiety disorder (GAD), differ from…
- Conditions
- Bipolar Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder Without Hyperactivity, Generalized Anxiety Disorder
- Trial name
- BBPP (NCT01570426)
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Bradley Hospital
Anxiety Disorder
Adjunctive Family CBT for Veterans With Anxiety
Despite the prevalence of posttraumatic stress disorder and anxiety disorders among Veterans, there has been limited focus on the development of interventions that include family members in treatments provided to Veterans.
- Trial name
- AF-CBT (NCT05340478)
- Testing
- Adjunctive Family - Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Anxiety Disorder
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT00236015
- Testing
- Gabitril
- Where
- 54 sites in United States, Canada
- Volunteers
- 880 people
- Sponsor
- Cephalon
Generalized Anxiety Disorder
A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder…
- Trial name
- NCT07856420
- Testing
- JNJ-99245354
- Where
- 4 sites in United States
- Volunteers
- 705 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Generalized Anxiety Disorder
Virtual Reality as Anxiety Management Tool for Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD) is a psychiatric disease characterized by long-lasting anxiety that is not focused on a specific object or situation.
- Trial name
- INTREPID (NCT00602212)
- Testing
- relaxation with virtual reality (VR), relaxation and biofeedback virtual reality
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Istituto Auxologico Italiano
Generalized Anxiety Disorder
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6…
- Trial name
- GAD (NCT00368745)
- Testing
- Pregabalin
- Where
- 21 sites in Costa Rica, Czechia and 5 more
- Volunteers
- 108 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pain, Anxiety
Pain, Anxiety, and Impacts on Oral Health-related Quality of Life for Patients With Orthodontic Treatment
The goal of this observational study is to learn about pain, anxiety, and impacts on oral health-related quality of life(OHRQoL) for patients before, during and after orthodontic treatment.
- Conditions
- Pain, Anxiety, Oral Health Related Quality of Life
- Trial name
- NCT06150911
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Treatment Adherence, Generalized Anxiety
Cerina-A Pilot Randomized Controlled Trial
The goal of this pilot Randomized Controlled Trial is twofold: 1) To learn about the feasibility and usefulness of a mobile application for generalised anxiety symptoms (Cerina); 2) To test the preliminary effects of Cerina in…
- Conditions
- Treatment Adherence, Generalized Anxiety, Treatment Adherence and Compliance
- Trial name
- Cerina (NCT06146530)
- Testing
- Treatment
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- Cerina Therapeutics
Generalized Anxiety Disorder
Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder
The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
- Trial name
- NCT00481325
- Testing
- pexacerfont, escitalopram
- Where
- 51 sites in United States
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Generalized Anxiety Disorder
Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)
There are few treatment options available for patients once they have failed standard psychopharmacological therapy for generalized anxiety disorder.
- Trial name
- NCT04557891
- Testing
- Active LIFUP Treatment
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder, Generalized Anxiety Disorder
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time.
- Trial name
- NCT05016050
- Testing
- HPDT-DA-013
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Happify Inc.
Generalized Anxiety Disorder
Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial
The use of Kava in Generalised Anxiety Disorder: an 18-week double-blind, randomised, placebo-controlled study.
- Trial name
- KGAD (NCT02219880)
- Testing
- Kava (240mg of kavalactones per day)
- Where
- 2 sites in Australia
- Volunteers
- 178 people
- Sponsor
- University of Melbourne
Anxiety
Clinical and Cost Effectiveness of Alpha-Stim AID CES
This is a single-centre research study in patients seen within an NHS Improving Access to Psychological Interventions (IAPT) service with suspected generalised anxiety disorder (GAD).
- Trial name
- NCT02901080
- Testing
- Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire
- Where
- United Kingdom
- Volunteers
- 161 people
- Sponsor
- Electromedical Products International, Inc.
Major Depression, Generalized Anxiety
Neural Mechanisms of Real-world Emotions and Internalizing
This study utilizes mobile health methods, including smartphone technology, subjective self-reports measures of emotion, behavioral tasks, functional Magnetic Resonance Imaging (fMRI), physiological measures of attention and…
- Conditions
- Major Depression, Generalized Anxiety, Emotions
- Trial name
- NCT07891624
- Testing
- Academic Performance Feedback
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University of Miami
Generalized Anxiety Disorder, Social Anxiety Disorder
Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
This proposed study aims to evaluate the efficacy of a daily oral cannabinoid oil preparation in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65…
- Conditions
- Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia
- Trial name
- NCT04569760
- Testing
- 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)
- Where
- Canada
- Sponsor
- McMaster University